[Interaction of cellular and humoral immunity factors in acute leukemia].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to V M Bergol'ts.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Studies on the cell immunity in patients with acute leukemia were conducted in two functionally different tests: in cytotoxic reaction of lymphocytes and in the reaction of inhibition of leucocytes adherence which manifest accordingly the killer and antigen-reactive function of immunocompetent cells. There was found a statistically reliable enhancement of lymphocytes reactivity in patients with acute leukemia against leukemia-associated antigens compared with lymphocytes of healthy donors. The cytotoxic activity of lymphocytes was enhanced during the complete remission and before the recurrence, whereas the potential of antigen-reactive cells was reduced during the complete remission and against the background of the recurrence.
Explore the source record for details and available documents.
In the paper, the main results of some investigations, conducted in the Institute laboratories during 1969--77, are summarized. Special attention is given to the detected first phenomenon of functional antagonism of antibodies in leukemia and to the recognition of the specific humoral immune responsiveness of acute leukemia patients. The author reports the results of clinical trials of "the method for regulation of the specific immunity", which practically gives a 100% remission in comparatively short terms for children with acute lymphoblastic leukemia. Also, a longer remission term and survival were gained in children, subjected in the remission period to chemotherapy in combination with BCG injections as compared with patients treated only by chemotherapy.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A possibility of detecting embryonic leukemic antigen on human leukemic blast cells in an acute human leukemia cytotoxicity test with the sera and 7S and 19S serum immunoglobulins of the placental blood was studied. The presence on the blast cells of patients suffering from acute leukemia of an antigen detectable by antibodies of placental blood (of parturients) was demonstrated; this antigen was absent on the leukocytes of healthy donors.
Explore the source record for details and available documents.
Studies on humoral immunity were performed in sarcoma patients before, during and after the treatment. Cytotoxic test was carried on with target cells of human mesenchymoma stable line. The activity of serum and its immunoglobulin fractions in 15 patients with soft tissue sarcoma and in 10 patients with congenital sarcoma was studied. It was found that 19S fraction of patient's blood serum contains cytotoxic antibodies. 7S fraction was permanently inactive. The whole serum was cytoloxic before the treatment in 8 of 12 patients with soft tissue sarcoma. Among 20 healthy donors only 3 were active. There was revealed a possibility of strong specific binding of 19S immunoglobulins (and more rarely of 7S immunoglobulins) with target-cells surface. It evidences the capacity of immunoglobulins to render not only cytotoxic action but also presumably, a blocking effect. Irradiation treatment in doses of 1800-9000 rad fail to diminish the cytotoxic activity of the whole serum and its 19S fraction.
Explore the source record for details and available documents.
There proved to be an increase in B-lymphocyte count (associated with increased synthesis of nonspecific immunoglobulins) in BALB/C mice highly sensitive to Rausher virus, after the administration of a relatively low dose of the virus. After the administration of the virus in combination with complete Freund's adjuvant in the spleen of mice, at the early periods of development of the disease, there were present normal cells synthesizing antibodies against the surface antigen of Rausher leukemia and leukemic cells with blocking antibodies adsorbed on their surface.
The therapeutic effect of cyclophosphamide (CP) in relation to the dose and rhythum of its administration was studied in C57BL/6 mice with a methycholanthrene-induced sarcoma. The optimal scheme giving a complete cure of the experimental animals was 5 injections, each of 199 mg/kg CP at intervals of 10 days. The effect of the total dose of CP on humoral antitumor immunity was demonstrated: after injection of 100 mg/kg CP the animals' serum lost its ability to stimulate tumor growth and acquired cytotoxic properties. The serum of animals receiving the total doses of CP above 400 mg/kg lost its effect on tumor growth. The doses of CP used did not affect cellular antitumor immunity (the cytotoxicity of the lymphocytes and resistance of the tumor to retransplantation.).
Explore the source record for details and available documents.
The article treats of the effect of cyclophosphamide (CP), and complete Freund's adjuvant (CFA) and their combination on the development of transplantable leukemia-hemocytoblastosis in mice and some host humoral immune reactions. The optimal combinations of the CP (on the 3rd day after the transplantation of leukemia) and of the CFA (on the 10th day) led to increase in the average survival up to 93,9 days (8.5 days in control). This combination also increased the survival of 42.9% of the animals for over 180 days. Enhancement of humoral immunity proved to take place in the course of chemoimmunotherapy. In spite of deep immunodepression after the CP and CFA administration the number of antibody-producing cells increased and enhancement of the cytotoxic activity of the serum IgM was observed.
Explore the source record for details and available documents.